2,592 reports of this reaction
2.6% of all DABIGATRAN ETEXILATE MESYLATE reports
#5 most reported adverse reaction
ANAEMIA is the #5 most commonly reported adverse reaction for DABIGATRAN ETEXILATE MESYLATE, manufactured by Boehringer Ingelheim Pharmaceuticals Inc.. There are 2,592 FDA adverse event reports linking DABIGATRAN ETEXILATE MESYLATE to ANAEMIA. This represents approximately 2.6% of all 101,632 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE MESYLATE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for DABIGATRAN ETEXILATE MESYLATE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for DABIGATRAN ETEXILATE MESYLATE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 2,592 FDA reports for DABIGATRAN ETEXILATE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.6% of all adverse event reports for DABIGATRAN ETEXILATE MESYLATE, making it a notable side effect.
If you experience anaemia while taking DABIGATRAN ETEXILATE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.